Supernus Historical Financial Ratios

SUPN Stock

USD 32.29 0.13 0.40%

Supernus Pharmaceuticals is promptly reporting on over 111 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 19.74, Free Cash Flow Yield of 0.0902, Invested Capital of 0.0 or Operating Cash Flow Per Share of 3.28 will help investors to properly organize and evaluate Supernus Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

About Supernus Financial Ratios Analysis

Supernus PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Supernus Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Supernus financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Supernus Pharmaceuticals history.

Supernus Pharmaceuticals Financial Ratios Chart

At this time, Supernus Pharmaceuticals' Inventory Turnover is very stable compared to the past year. As of the 29th of March 2025, Net Income Per Share is likely to grow to 1.41, while Price To Sales Ratio is likely to drop 2.86.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Inventory Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Supernus Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Supernus Pharmaceuticals sales, a figure that is much harder to manipulate than other Supernus Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Supernus Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Supernus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.At this time, Supernus Pharmaceuticals' Inventory Turnover is very stable compared to the past year. As of the 29th of March 2025, Net Income Per Share is likely to grow to 1.41, while Price To Sales Ratio is likely to drop 2.86.

	2022	2023	2024	2025 (projected)
Payables Turnover	8.27	42.66	16.98	17.83
Days Of Inventory On Hand	383.08	337.24	254.37	241.65

Payables Turnover Days Of Inventory On Hand

Supernus Pharmaceuticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.15	0.79	-0.47	-0.92	-0.8	0.2	0.15	0.97	-0.8	-0.68	-0.58	-0.1	0.01	-0.32	0.17	0.97	-0.04	-0.53	-0.47	-0.39	-0.51	0.01	-0.13	0.42	-0.57
Ptb Ratio	0.15		0.1	-0.12	-0.03	-0.04	0.17	1.0	0.22	-0.04	0.13	0.08	0.27	-0.85	-0.13	0.11	0.07	-0.32	0.32	0.32	0.51	0.31	-0.85	-0.07	-0.36	0.28
Days Sales Outstanding	0.79	0.1		-0.17	-0.79	-0.62	0.27	0.1	0.77	-0.62	-0.82	-0.36	-0.24	-0.05	-0.15	-0.13	0.77	0.27	-0.76	-0.53	-0.61	-0.75	-0.05	-0.1	0.11	-0.78
Book Value Per Share	-0.47	-0.12	-0.17		0.64	0.8	-0.67	-0.12	-0.47	0.8	0.41	0.88	0.31	-0.34	0.69	-0.54	-0.51	0.73	0.1	0.04	0.15	0.07	-0.34	0.32	-0.31	0.18
Free Cash Flow Yield	-0.92	-0.03	-0.79	0.64		0.94	-0.46	-0.03	-0.91	0.94	0.86	0.75	0.31	-0.24	0.39	-0.23	-0.95	0.19	0.6	0.53	0.57	0.58	-0.24	0.15	-0.43	0.66
Operating Cash Flow Per Share	-0.8	-0.04	-0.62	0.8	0.94		-0.63	-0.04	-0.77	1.0	0.79	0.87	0.47	-0.27	0.46	-0.39	-0.83	0.38	0.42	0.48	0.42	0.39	-0.27	0.14	-0.31	0.49
Capex To Depreciation	0.2	0.17	0.27	-0.67	-0.46	-0.63		0.17	0.21	-0.63	-0.56	-0.6	-0.57	0.14	-0.44	0.27	0.25	-0.5	-0.27	-0.19	-0.18	-0.24	0.14	-0.21	-0.16	-0.33
Pb Ratio	0.15	1.0	0.1	-0.12	-0.03	-0.04	0.17		0.22	-0.04	0.13	0.08	0.27	-0.85	-0.13	0.11	0.07	-0.32	0.32	0.32	0.51	0.31	-0.85	-0.07	-0.36	0.28
Ev To Sales	0.97	0.22	0.77	-0.47	-0.91	-0.77	0.21	0.22		-0.77	-0.66	-0.57	0.06	-0.01	-0.32	0.17	0.99	-0.13	-0.51	-0.46	-0.38	-0.5	-0.01	-0.13	0.52	-0.56
Free Cash Flow Per Share	-0.8	-0.04	-0.62	0.8	0.94	1.0	-0.63	-0.04	-0.77		0.8	0.87	0.47	-0.27	0.46	-0.39	-0.83	0.38	0.42	0.48	0.42	0.39	-0.27	0.14	-0.31	0.49
Roic	-0.68	0.13	-0.82	0.41	0.86	0.79	-0.56	0.13	-0.66	0.8		0.63	0.54	-0.28	0.2	-0.12	-0.73	-0.04	0.74	0.58	0.72	0.71	-0.28	0.04	-0.16	0.77
Inventory Turnover	-0.58	0.08	-0.36	0.88	0.75	0.87	-0.6	0.08	-0.57	0.87	0.63		0.39	-0.42	0.63	-0.63	-0.63	0.45	0.32	0.34	0.38	0.3	-0.42	0.24	-0.34	0.38
Net Income Per Share	-0.1	0.27	-0.24	0.31	0.31	0.47	-0.57	0.27	0.06	0.47	0.54	0.39		-0.3	0.05	-0.12	-0.03	0.06	0.25	0.17	0.36	0.24	-0.3	-0.1	0.42	0.28
Days Of Inventory On Hand	0.01	-0.85	-0.05	-0.34	-0.24	-0.27	0.14	-0.85	-0.01	-0.27	-0.28	-0.42	-0.3		-0.18	0.09	0.15	-0.12	-0.36	-0.22	-0.61	-0.34	1.0	-0.07	0.57	-0.37
Payables Turnover	-0.32	-0.13	-0.15	0.69	0.39	0.46	-0.44	-0.13	-0.32	0.46	0.2	0.63	0.05	-0.18		-0.34	-0.33	0.27	0.12	-0.1	0.06	0.1	-0.18	0.87	-0.18	0.14
Average Inventory	0.17	0.11	-0.13	-0.54	-0.23	-0.39	0.27	0.11	0.17	-0.39	-0.12	-0.63	-0.12	0.09	-0.34		0.18	-0.46	0.05	0.13	0.03	0.05	0.09	0.08	0.09	0.04
Capex To Revenue	0.97	0.07	0.77	-0.51	-0.95	-0.83	0.25	0.07	0.99	-0.83	-0.73	-0.63	-0.03	0.15	-0.33	0.18		-0.12	-0.57	-0.53	-0.48	-0.56	0.15	-0.13	0.58	-0.62
Cash Per Share	-0.04	-0.32	0.27	0.73	0.19	0.38	-0.5	-0.32	-0.13	0.38	-0.04	0.45	0.06	-0.12	0.27	-0.46	-0.12		-0.29	-0.26	-0.22	-0.31	-0.12	-0.08	-0.23	-0.21
Pocfratio	-0.53	0.32	-0.76	0.1	0.6	0.42	-0.27	0.32	-0.51	0.42	0.74	0.32	0.25	-0.36	0.12	0.05	-0.57	-0.29		0.45	0.87	1.0	-0.36	0.06	-0.25	0.99
Interest Coverage	-0.47	0.32	-0.53	0.04	0.53	0.48	-0.19	0.32	-0.46	0.48	0.58	0.34	0.17	-0.22	-0.1	0.13	-0.53	-0.26	0.45		0.43	0.43	-0.22	-0.09	-0.28	0.48
Capex To Operating Cash Flow	-0.39	0.51	-0.61	0.15	0.57	0.42	-0.18	0.51	-0.38	0.42	0.72	0.38	0.36	-0.61	0.06	0.03	-0.48	-0.22	0.87	0.43		0.86	-0.61	-0.01	-0.34	0.86
Pfcf Ratio	-0.51	0.31	-0.75	0.07	0.58	0.39	-0.24	0.31	-0.5	0.39	0.71	0.3	0.24	-0.34	0.1	0.05	-0.56	-0.31	1.0	0.43	0.86		-0.34	0.05	-0.24	0.99
Days Payables Outstanding	0.01	-0.85	-0.05	-0.34	-0.24	-0.27	0.14	-0.85	-0.01	-0.27	-0.28	-0.42	-0.3	1.0	-0.18	0.09	0.15	-0.12	-0.36	-0.22	-0.61	-0.34		-0.07	0.57	-0.37
Income Quality	-0.13	-0.07	-0.1	0.32	0.15	0.14	-0.21	-0.07	-0.13	0.14	0.04	0.24	-0.1	-0.07	0.87	0.08	-0.13	-0.08	0.06	-0.09	-0.01	0.05	-0.07		-0.08	0.06
Roe	0.42	-0.36	0.11	-0.31	-0.43	-0.31	-0.16	-0.36	0.52	-0.31	-0.16	-0.34	0.42	0.57	-0.18	0.09	0.58	-0.23	-0.25	-0.28	-0.34	-0.24	0.57	-0.08		-0.26
Ev To Operating Cash Flow	-0.57	0.28	-0.78	0.18	0.66	0.49	-0.33	0.28	-0.56	0.49	0.77	0.38	0.28	-0.37	0.14	0.04	-0.62	-0.21	0.99	0.48	0.86	0.99	-0.37	0.06	-0.26

Click cells to compare fundamentals

Supernus Pharmaceuticals Account Relationship Matchups

Supernus Pharmaceuticals fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	3.17	2.54	2.67	2.6	3.01	2.86
Ptb Ratio	1.78	1.9	2.16	1.71	1.92	1.51
Days Sales Outstanding	98.81	93.76	90.53	86.61	78.36	129.35
Book Value Per Share	14.16	15.36	16.51	16.9	18.8	19.74
Free Cash Flow Yield	0.1	0.0808	0.0608	0.07	0.0859	0.0902
Operating Cash Flow Per Share	2.63	2.39	2.18	2.04	3.12	3.28
Stock Based Compensation To Revenue	0.0318	0.0309	0.0263	0.044	0.0419	0.0398
Capex To Depreciation	0.19	0.0627	0.004816	0.006493	0.009016	0.008565
Pb Ratio	1.78	1.9	2.16	1.71	1.92	1.51
Ev To Sales	2.74	3.05	3.39	2.54	2.96	2.81
Free Cash Flow Per Share	2.56	2.36	2.17	2.03	3.11	3.26
Roic	0.1	0.0453	0.0473	(0.002515)	0.0569	0.0598
Inventory Turnover	1.09	0.87	0.95	1.08	1.43	1.51
Net Income Per Share	2.16	2.41	1.01	0.0241	1.34	1.41
Days Of Inventory On Hand	336.24	417.99	383.08	337.24	254.37	241.65
Payables Turnover	8.53	8.04	8.27	42.66	16.98	17.83
Sales General And Administrative To Revenue	0.29	0.3	0.13	0.18	0.16	0.14
Capex To Revenue	0.006628	0.003527	6.17E-4	9.07E-4	0.001095	0.001041
Cash Per Share	8.03	6.4	8.6	4.67	8.23	8.64
Pocfratio	9.57	12.18	16.39	14.21	11.59	8.75
Interest Coverage	7.31	3.67	9.52	(2.18)	(1.96)	(2.06)
Capex To Operating Cash Flow	0.0249	0.0161	0.003527	0.00496	0.004216	0.004006
Pfcf Ratio	9.81	12.38	16.44	14.28	11.64	9.54
Days Payables Outstanding	42.77	45.37	44.12	8.56	21.49	20.42
Income Quality	1.09	2.38	1.92	84.41	2.33	2.21
Roe	0.17	0.0655	0.0685	0.001428	0.0713	0.0678
Ev To Operating Cash Flow	10.3	13.89	19.34	13.91	11.38	10.2
Pe Ratio	10.43	28.98	31.53	1.2K	26.97	25.63
Ev To Free Cash Flow	10.56	14.11	19.41	13.98	11.43	11.29
Earnings Yield	0.0959	0.0345	0.0317	8.34E-4	0.0371	0.0389
Intangibles To Total Assets	0.29	0.53	0.48	0.56	0.47	0.49
Net Debt To E B I T D A	0.48	1.68	2.25	(0.37)	(0.2)	(0.19)
Current Ratio	2.57	1.91	1.07	1.7	2.35	3.48
Tangible Book Value Per Share	5.75	(1.63)	1.24	3.75	7.2	7.56
Receivables Turnover	3.69	3.89	4.03	4.21	4.66	4.86
Graham Number	27.72	18.65	20.5	3.03	23.81	25.0
Shareholders Equity Per Share	14.16	15.36	16.51	16.9	18.8	19.74

Pair Trading with Supernus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Supernus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Supernus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Supernus Stock

0.69

ELEV

Elevation Oncology

Pair Corr

Moving against Supernus Stock

0.83	GILD	Gilead Sciences	Pair Corr
0.82	OCX	OncoCyte Corp	Pair Corr
0.72	AZN	AstraZeneca PLC ADR	Pair Corr
0.63	SNY	Sanofi ADR	Pair Corr
0.62	GOSS	Gossamer Bio	Pair Corr

The ability to find closely correlated positions to Supernus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Supernus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Supernus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Supernus Pharmaceuticals to buy it.

The correlation of Supernus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Supernus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Supernus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Supernus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Supernus Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Supernus Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Supernus Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Supernus Pharmaceuticals Stock:

How To Invest In Supernus

Details

Is Supernus Stock a good investment?

Details

What is Supernus Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

14.447

Earnings Share

1.32

Revenue Per Share

12.011

Quarterly Revenue Growth

0.06

Return On Assets

0.029

The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Supernus Historical Financial Ratios

About Supernus Financial Ratios Analysis

Supernus Pharmaceuticals Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Inventory Turnover

Supernus Pharmaceuticals fundamentals Correlations

Supernus Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Supernus Pharmaceuticals fundamentals Accounts

Pair Trading with Supernus Pharmaceuticals

Moving together with Supernus Stock

Moving against Supernus Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Days Payables Outstanding	+ 1.0	Days Of Inventory On Hand
Pfcf Ratio	+ 1.0	Pocfratio
Capex To Revenue	+ 0.99	Ev To Sales
Ev To Operating Cash Flow	+ 0.99	Pocfratio

Capex To Revenue	- 0.95	Free Cash Flow Yield
Free Cash Flow Yield	- 0.92	Price To Sales Ratio
Ev To Sales	- 0.91	Free Cash Flow Yield
Days Payables Outstanding	- 0.85	Pb Ratio
Days Of Inventory On Hand	- 0.85	Pb Ratio
Days Payables Outstanding	- 0.85	Ptb Ratio